Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Clin Pharmacokinet. 2012 Dec;51(12):809–822. doi: 10.1007/s40262-012-0012-y

Figure 5.

Figure 5

Visual predictive checks for lamivudine administered at 300 mg daily at each sampling period in both blood plasma and cervicovaginal fluid using the 5th and 95th percentiles and median of 1,000 simulated subjects and observed data at both first dose and multiple dose: a blood plasma at first dose; b cervicovaginal fluid at first dose; c blood plasma at multiple dose; d cervicovaginal fluid at multiple dose. 3TC lamivudine, BP blood plasma, CVF cervicovaginal fluid